// App-Quantinova.ai

2503 : Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.

Researchers

Presenter

  • Sara M. Tolaney

Principal Investigators

  • John Frederick Hilton

  • James M. Cleary

  • Leena Gandhi

  • Eunice Lee Kwak

  • Jeffrey W. Clark

  • Andrew Wolanski

  • Tracy Demeo Bell

  • Scott J. Rodig

  • Judy H. Chiao

  • David Blake

  • Geoffrey Shapiro

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada, Ottawa, ON, Canada

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Department of Pathology, Division of Hematopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

  • Cyclacel Ltd, Berkeley Heights, NJ

  • Cyclacel, Dundee, United Kingdom

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • Cyclacel Pharmaceuti

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • sapacitabine

  • Seliciclib

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT00999401

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved